Lene H. S. Veiga

Lene H. S. Veiga

Auto-generated profile, based on publicly available information

Lene H. S. Veiga

Division of Cancer Epidemiology and Genetics, National Cancer Institute , Bethesda, MD

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
LVLene H.S. Veiga
Lene H.S. Veiga
PBParveen Bhatti
Parveen Bhatti
CRCécile M. Ronckers
Cécile M. Ronckers
ASAlice J. Sigurdson
Alice J. Sigurdson
MSMarilyn Stovall
Marilyn Stovall
PIPeter D. Inskip
Peter D. Inskip
Background: Although ionizing radiation is an established environmental risk factor for thyroid cancer, the effect of chemotherapy drugs on thyroid cancer risk remains unclear. We evaluated the chemotherapy-related risk of thyroid cancer in childhood cancer survivors and the possible joint effects of chemotherapy and radiotherapy. Methods: The study included 12,547 five-year survivors of childhood cancer diagnosed during 1970 through 1986. Chemotherapy and radiotherapy information was obtained from medical records, and radiation dose was estimated to the thyroid gland. Cumulative incidence and relative risks were calculated with life-table methods and Poisson regression. Chemotherapy-related risks were evaluated separately by categories of radiation dose. Results: Histologically confirmed thyroid cancer occurred in 119 patients. Thirty years after the first childhood cancer treatment, the cumulative incidence of thyroid cancer was 1.3% (95% CI, 1.0–1.6) for females and 0.6% (0.4–0.8) for males. Among patients with thyroid radiation doses of 20 Gy or less, treatment with alkylating agents was associated with a significant 2.4-fold increased risk of thyroid cancer (95% CI, 1.3–4.5; P = 0.002). Chemotherapy risks decreased as radiation dose increased, with a significant decrease for patients treated with alkylating agents (Ptrend = 0.03). No chemotherapy-related risk was evident for thyroid radiation doses more than 20 Gy. Conclusions: Treatments with alkylating agents increased thyroid cancer risk, but only in the radiation dose range less than 20 Gy, in which cell sparing likely predominates over cell killing. Impact: Our study adds to the evidence for chemotherapy agent–specific increased risks of thyroid cancer, which to date, were mainly thought to be related to prior radiotherapy. Cancer Epidemiol Biomarkers Prev; 21(1); 92–101. ©2011 AACR.

8 May 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
JVJacqueline B Vo
Jacqueline B Vo
CRCody Ramin
Cody Ramin
LVLene H S Veiga
Lene H S Veiga
CBCarolyn Brandt
Carolyn Brandt
RCRochelle E Curtis
Rochelle E Curtis
AGAmy Berrington de González
Amy Berrington de González
Although breast cancer survivors are at risk for cardiovascular disease (CVD) from treatment late effects, evidence to inform long-term and age-specific cardiovascular surveillance recommendations is lacking. We conducted a retrospective cohort study of 10 211 women diagnosed with first primary unilateral breast cancer in Kaiser Permanente Washington or Colorado (aged 20 years and older, survived ≥1 year). We estimated multivariable adjusted hazard ratios (HRs) for associations between initial chemotherapy regimen type (anthracycline and/or trastuzumab, other chemotherapies, no chemotherapy [referent]) and CVD risk, adjusted for patient characteristics, other treatments, and CVD risk factors. Cumulative incidence was calculated considering competing events. After 5.79 median years, 14.67% of women developed CVD (cardiomyopathy and/or heart failure [HF], ischemic heart disease, stroke). Women treated with anthracyclines and/or trastuzumab had a higher risk of CVD compared with no chemotherapy (adjusted HR = 1.53, 95% confidence interval [CI] = 1.31 to 1.79), persisting at least 5 years postdiagnosis (adjusted HR5-<10 years = 1.85, 95% CI = 1.44 to 2.39; adjusted HR≥10 years = 1.83, 95% CI = 1.34 to 2.49). Cardiomyopathy and/or HF risks were elevated among women treated with anthracyclines and/or trastuzumab compared with no chemotherapy, especially for those aged younger than 65 years (adjusted HR20-54years = 2.97, 95% CI = 1.72 to 5.12; adjusted HR55-64years = 2.21, 95% CI = 1.52 to 3.21), differing for older women (adjusted HR≥65 years = 1.32, 95% CI = 0.97 to 1.78), and at least 5 years postdiagnosis (adjusted HR5-<10years = 1.89, 95% CI = 1.35 to 2.64; adjusted HR≥10 years = 2.21, 95% CI = 1.52 to 3.20). Anthracyclines and/or trastuzumab receipt was associated with increased ischemic heart disease risks after 5 or more years (adjusted HR5-<10years = 1.51, 95% CI = 1.06 to 2.14; adjusted HR≥10 years = 1.86, 95% CI = 1.18 to 2.93) with no clear age effects, and stroke risk (adjusted HR = 1.33, 95% CI = 1.05 to 1.69), which did not vary by time or age. There was some evidence of long-term cardiomyopathy and/or HF and ischemic heart disease risks with other chemotherapies. Among women aged younger than 65 treated with anthracyclines and/or trastuzumab, up to 16% developed CVD by 10 years (20-54 years = 6.91%; 55-64 years = 16.00%), driven by cardiomyopathy and/or HF (20-54 years = 3.90%; 55-64 years = 9.78%). We found increased long-term risks of cardiomyopathy and/or HF and ischemic heart disease among breast cancer survivors treated with anthracyclines and/or trastuzumab and increased cardiomyopathy and/or HF risk among women aged younger than 65 years.

2 February 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
JVJacqueline B. Vo
Jacqueline B. Vo
CRCody Ramin
Cody Ramin
ABAna Barac
Ana Barac
AGAmy Berrington de Gonzalez
Amy Berrington de Gonzalez
LVLene Veiga
Lene Veiga
Purpose: Heart disease is a significant concern among breast cancer survivors, in part due to cardiotoxic treatments including chemotherapy and radiotherapy. Long-term trends in heart disease mortality have not been well characterized. We examined heart disease mortality trends among US breast cancer survivors by treatment type. Methods: We included first primary invasive breast cancer survivors diagnosed between 1975 and 2016 (aged 18–84; survived 12 + months; received initial chemotherapy, radiotherapy, or surgery) in the SEER-9 Database. Standardized mortality ratios (SMRs) and 10-year cumulative heart disease mortality estimates accounting for competing events were calculated by calendar year of diagnosis and initial treatment regimen. Ptrends were assessed using Poisson regression. All statistical tests were 2-sided. Results: Of 516,916 breast cancer survivors, 40,812 died of heart disease through 2017. Heart disease SMRs declined overall from 1975–1979 to 2010–2016 (SMR 1.01 [95%CI: 0.98, 1.03] to 0.74 [0.69, 0.79], ptrend < 0.001). This decline was also observed for survivors treated with radiotherapy alone and chemotherapy plus radiotherapy. A sharper decline in heart disease SMRs was observed from 1975 to 1989 for left-sided radiotherapy, compared to right-sided. In contrast, there was a non-significant increasing trend in SMRs for chemotherapy alone, and significant by regional stage (ptrend = 0.036). Largest declines in 10-year cumulative mortality were observed from 1975–1984 to 2005–2016 among surgery only: 7.02% (95%CI: 6.80%, 7.23%) to 4.68% (95%CI: 4.39%, 4.99%) and radiotherapy alone: 6.35% (95%CI: 5.95%, 6.77%) to 2.94% (95%CI: 2.73%, 3.16%). Conclusions: We observed declining heart disease mortality trends by most treatment types yet increasing for regional stage patients treated with chemotherapy alone, highlighting a need for additional studies with detailed treatment data and cardiovascular management throughout cancer survivorship.

11 October 2022 in The Lancet Oncology
Verified
Journal Article
Closed access
LVLene H S Veiga
Lene H S Veiga
JVJacqueline B Vo
Jacqueline B Vo
RCRochelle E Curtis
Rochelle E Curtis
MMMatthew M Mille
Matthew M Mille
CLChoonsik Lee
Choonsik Lee
AGAmy Berrington de Gonzalez
Amy Berrington de Gonzalez

6 October 2022 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DWDiana R. Withrow
Diana R. Withrow
HAHarald Anderson
Harald Anderson
GAGregory T. Armstrong
Gregory T. Armstrong
MHMichael Hawkins
Michael Hawkins
NJNeige M.Y. Journy
Neige M.Y. Journy
LVLene H. S. Veiga
Lene H. S. Veiga
Importance: Meningioma is the most common subsequent neoplasm following cranial irradiation among survivors of childhood cancer, but there are still uncertainties regarding the magnitude of the radiation dose-response association, potential modifiers of radiation risks, and the role of chemotherapy.Objective: To evaluate meningioma risk in survivors of childhood cancer following radiotherapy and chemotherapy and identify possible modifying factors of radiation-associated risk.Design, Setting, and Participants: This international case-control study pooled data from 4 nested case-control studies of survivors of childhood cancer diagnosed between 1942 and 2000, followed through 2016. Cases were defined as participants diagnosed with a subsequent meningioma. Controls were matched to cases based on sex, age at first cancer diagnosis, and duration of follow-up. Data were analyzed from July 2019 to June 2022.Exposures: Radiation dose (Gy) to the meningioma site and cumulative chemotherapy doses, including intrathecal and systemic methotrexate doses.Main Outcomes and Measures: The main outcome was subsequent meningioma, assessed using odds ratios (ORs) and excess odds ratios per gray (EOR/Gy).Results: The analysis included 273 survivors of childhood cancer who developed meningioma (cases) and 738 survivors who did not (controls), with a total of 1011 individuals (median [IQR] age at first cancer diagnosis 5.0 [3.0-9.2] years; 599 [59.2%] female). Median (IQR) time since first cancer was 21.5 (15.0-27.0) years. Increasing radiation dose was associated with increased risk of meningioma (EOR/Gy, 1.44; 95% CI, 0.62-3.61), and there was no evidence of departure from linearity (P = .90). Compared with survivors who were not exposed to radiation therapy, those who received doses of 24 Gy or more had more than 30-fold higher odds of meningioma (OR, 33.66; 95% CI, 14.10-80.31). The radiation dose-response association was significantly lower among patients treated at age 10 years or older compared with those treated before age 10 years (EOR/Gy, 0.57; 95% CI, 0.18-1.91 vs 2.20; 95% CI, 0.87-6.31; P for heterogeneity = .03). Risk associated with radiation remained significantly elevated 30 years after exposure (EOR/Gy, 3.76; 95% CI, 0.77-29.15). We found an increased risk of meningioma among children who had received methotrexate (OR, 3.43; 95% CI, 1.56-7.57), but no evidence of a dose-response association or interaction with radiation dose.Conclusions and Relevance: These findings suggest that the meninges are highly radiosensitive, especially for children treated before age 10 years. These results support the reduction in whole-brain irradiation over recent decades and the prioritization of approaches that limit radiation exposure in healthy tissue for children. The persistence of elevated risks of meningiomas for 30 years after cranial radiotherapy could help inform surveillance guidelines.

14 November 2025 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
LVLene H. S. Veiga
Lene H. S. Veiga
GGGretchen L. Gierach
Gretchen L. Gierach
SSSusan A. Smith
Susan A. Smith
RHRebecca M. Howell
Rebecca M. Howell
MMMatthew M. Mille
Matthew M. Mille
AGAmy Berrington de Gonzalez
Amy Berrington de Gonzalez
Background: Radiotherapy increases contralateral breast cancer risk, while hormone therapy reduces it; their combined effects are unclear. Methods: Data from two US retrospective cohort studies of 5-year breast cancer survivors (stage I-III, ages 20–84), Kaiser Permanente (KP, 1990–2012) and SEER (1990–2013), were analysed. Contralateral breast radiation doses were estimated for the KP cohort. Multivariable Poisson regression estimated relative risks (RRs) and excess relative risks per Gray (ERR/Gy), stratified by hormone therapy use. Results: KP cohort ( n = 9053) included 353 contralateral breast cancer cases (73% ER+); SEER cohort ( n = 244,834) included 10,470 cases (72% ER+). Among women with ER+ first breast cancer, radiotherapy increased the risk of ER+ contralateral breast cancer in non-users of hormone therapy (KP RR = 2.2, 95%CI:1.20–4.14; SEER RR = 1.12, 1.04–1.21), but not in users (KP RR = 0.88, 0.61–1.26; SEER RR = 1.03, 0.94–1.12). In KP, higher radiation dose increased risk of ER+ contralateral breast cancer among non-users (ERR/Gy=1.39, 95%CI:0.33,3.66), but not among users (ERR/Gy= –0.13, –0.36,0.23). Radiotherapy also increased risk of ER– contralateral breast cancer (KP RR = 1.85, 95%CI: 0.95–3.59; SEER RR = 1.12, 1.01–1.23), especially in younger exposed women (SEER RR = 1.31, 1.02-1.69 for age <40 vs 40+ years). Additionally, the risk increased linearly with radiation dose to the contralateral breast (ERR/Gy=0.87, 0.04,2.72). Conclusions: Radiotherapy increased contralateral breast cancer risk, but hormone therapy appeared to mitigate this risk for ER+ cases. These findings have important implications for individuals exposed to chest radiation.